.jpg?sfvrsn=ac4b0b4b_1)
Centre for Cancer Drug Discovery
The Centre for Cancer Drug Discovery at The Institute of Cancer Research, London, is the largest academic cancer drug discovery and development group worldwide. Its research groups cover every aspect of new drug discovery and development, from cell and molecular biology through to chemical synthesis of new agents and their evaluation in clinical trials.
The Centre for Cancer Drug Discovery is based in a state-of-the-art £75m building on our Sutton campus, opened in 2020.
Join us and discover new cancer drugs
The ICR is making a significant investment in the Division of Cancer Therapeutics – which encompasses the Centre for Cancer Drug Discovery – with the recruitment of new senior Faculty in the Centre for Cancer Drug Discovery, the Centre for Protein Degradation and the Centre for Target Validation.
Our mission
The mission of the Centre for Cancer Drug Discovery is:
- To discover and develop effective therapeutics for the treatment of cancer.
- Exploit the addictions, dependencies and vulnerabilities of cancer cells to develop innovative small molecule drugs.
- Prioritise novelty and unmet clinical need in defined patient populations.
Our record of achievement
Since 2005, research teams now based in the Centre for Cancer Drug Discovery have:
- Discovered 21 clinical candidates
- 13 of which have entered clinical trials.
The ICR's researchers also discovered abiraterone, which was approved by NICE in 2012, and is widely used to treat advanced prostate cancer across the world.
